clinical trial · NCT07302360
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
Xian-Janssen Pharmaceutical Ltd.·—·recruiting·n = 200
Colitis, Ulcerative
brief summary
The purpose of this study is to assess the measurable changes in health, function, or quality of life (clinical outcomes) after receiving guselkumab in real-world clinical practice amongst Chinese participants with ulcerative colitis (UC; a long-term disease of the large intestine in which the lining of the colon \[part of large intestine\] becomes inflamed and develops tiny open ulcers), who have not received biologic therapy (a medicine made from living organisms or their components) previously.
started
Dec 11, 2025
primary completion
Jun 30, 2028
completion
Jun 30, 2028
last updated
Jul 6, 2026
official title
Guselkumab Real-world Effectiveness Among Bio-NaÏve Patients With Moderate-to-severe Ulcerative Colitis in China: A Multicenter, Non-interventional, Prospective Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol